2015
DOI: 10.3390/pharmaceutics7040438
|View full text |Cite
|
Sign up to set email alerts
|

Transdermal Drug Delivery: Innovative Pharmaceutical Developments Based on Disruption of the Barrier Properties of the Stratum Corneum

Abstract: The skin offers an accessible and convenient site for the administration of medications. To this end, the field of transdermal drug delivery, aimed at developing safe and efficacious means of delivering medications across the skin, has in the past and continues to garner much time and investment with the continuous advancement of new and innovative approaches. This review details the progress and current status of the transdermal drug delivery field and describes numerous pharmaceutical developments which have… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
563
0
22

Year Published

2016
2016
2024
2024

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 819 publications
(586 citation statements)
references
References 157 publications
(304 reference statements)
1
563
0
22
Order By: Relevance
“…All of these methods have respective weaknesses, for instance, the complexity design of prodrugs, irritation or toxicity of chemical enhancers, pain and damage of tissue caused by iontophoresis or noncavitational ultrasound and complex device design of electroporation, etc. [3][4][5][6] Pharmaceutical cocrystals can be defined as a stoichiometric multiple component supramolecular structure combined by an active pharmaceutical ingredient (API) and one or more unique cocrystal formers with non-covalent bonds. 7 Formation of pharmaceutical cocrystals can dramatically ameliorate the physicochemical properties of the API without any disruption of covalent bonds, including melting point, solubility, dissolution rate, stability 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 4 and mechanical behavior, etc.…”
Section: Introductionmentioning
confidence: 99%
“…All of these methods have respective weaknesses, for instance, the complexity design of prodrugs, irritation or toxicity of chemical enhancers, pain and damage of tissue caused by iontophoresis or noncavitational ultrasound and complex device design of electroporation, etc. [3][4][5][6] Pharmaceutical cocrystals can be defined as a stoichiometric multiple component supramolecular structure combined by an active pharmaceutical ingredient (API) and one or more unique cocrystal formers with non-covalent bonds. 7 Formation of pharmaceutical cocrystals can dramatically ameliorate the physicochemical properties of the API without any disruption of covalent bonds, including melting point, solubility, dissolution rate, stability 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 4 and mechanical behavior, etc.…”
Section: Introductionmentioning
confidence: 99%
“…Methods modifying the barrier properties can be passive or active. Passive methods include the influencing of drug and vehicle interactions and optimization of formulation to modify SC structure [104]. A widely used passive method is the application of chemical penetration enhancers that facilitate drug permeation across the skin.…”
Section: Transdermal Drug Deliverymentioning
confidence: 99%
“…The use of MNs is preferred because these devices are inexpensive and offer more reliable mode of administration by improving the pharmacokinetic and pharmacodynamics profiles of drugs [21]. MNs induce faster healing at administration site compared to hypodermic needles while allowing for a controlled rate of drug delivery [22]. Passive approaches, such as penetration enhancers, result in skin irritation and are limited to only small molecules [6,21].…”
Section: Introductionmentioning
confidence: 99%